Novartis’s push into oncology and liver disease, two of its treatment priorities, advanced on Monday as the Swiss drugmaker won a second U.S. breakthrough tag for its cancer gene therapy while striking a separate pact with Allergan.
The Basel-based drugmaker’s chimeric antigen receptor therapy (CAR-T) treatment, called CTL019, was awarded the U.S. Food and Drug Administration’s breakthrough therapy designation for adults with relapsed/refractory (r/r) diffuse large B-cell lymphoma, a common blood cancer.
Source: Reuters
Filed Under: Drug Discovery
